CL
Barclays hit the brakes a little
Barclays didn’t exactly dump Colgate-Palmolive — it kept the stock at Equal-Weight — but it did shave the price target from $88 to $79. That’s a pretty clear signal that the firm sees less upside than it did before, even if it’s not pounding the table on the bearish side.
What that means for your portfolio
An Equal-Weight rating is basically Wall Street’s shrug: the stock should do about as well as the market, give or take. Lowering the target, though, is the part investors usually notice. It can put a lid on near-term enthusiasm, especially for a defensive consumer staples name where people often expect boring-but-steady, not surprise drama.
The valuation tug-of-war
GuruFocus says Colgate’s GF Value is $91.83 versus a current price of $84.16, which implies the shares are still trading below that estimate of fair value. So you’ve got the classic setup: one model says “looks cheap,” while Barclays says “maybe not quite as cheap as before.”
The insider-selling wrinkle
There’s also the extra spice of $25.1 million in insider sales over the last three months. That doesn’t automatically mean trouble, but when insiders are cashing out and analysts are trimming targets, it can make investors a little more cautious.
Big picture: Colgate still looks like the dependable, toothpaste-and-maybe-a-slightly-sleepy-stock kind of company — but Barclays just turned the volume down a few notches.